More trials urged

February 1, 2004

Basel, Switzerland - Completely resected high-risk malignant melanoma patients who were treated with adjuvant extended-duration low-dose interferon did not have a significant survival benefit over patients who were only observed after surgery to remove the cancer, according to a new study.